(Q40987050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Sang Hyoung Park

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Young-Ho Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ji Hyun Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hyeok Jin Kwon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Suck-Ho Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Dong Il Park

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hyung Kil Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jong Pil Im

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

You Sun Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sung Young Lee

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sang Joon Lee

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Gastroenterology & Hepatology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

9 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

35-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Inflammatory bowel disease: clinical aspects and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Use of the tumor necrosis factor-blockers for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Could early anti-tumor necrosis factor therapy change the prognosis of Crohn's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Crohn's disease management after intestinal resection: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Postmarketing surveillance for drug safety: surely we can do better

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Drug development in inflammatory bowel disease: the role of the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091309

10.1586/17474124.2015.1091309

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json

release_ibwomhojijbmjmdxyzrvl64c5a

24 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibwomhojijbmjmdxyzrvl64c5a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26395533%20AND%20SRC:MED&resulttype=core&format=json